» Authors » J Jan B van Lanschot

J Jan B van Lanschot

Explore the profile of J Jan B van Lanschot including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 129
Citations 4367
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Yang Y, Liu Z, Wong I, Gao X, Zhang H, Liu J, et al.
Br J Surg . 2025 Feb; 112(2). PMID: 39937490
Background: Neoadjuvant chemoradiotherapy (nCRT) in patients with oesophageal squamous cell carcinoma (OSCC) may lead to clinical complete response (cCR). It is important to know the accuracy of clinical response evaluations...
2.
Overtoom H, Eyck B, van der Wilk B, Noordman B, van der Sluis P, Wijnhoven B, et al.
Ann Surg . 2024 Aug; PMID: 39140597
Objective: To investigate whether prolonged time to surgery negatively affects survival, pathological outcome or postoperative complications in patients with histologically proven residual disease after neoadjuvant chemoradiotherapy for locally advanced esophageal...
3.
van der Zijden C, van der Sluis P, Mostert B, Nuyttens J, van Lanschot J, Spaander M, et al.
Ann Surg Oncol . 2024 Jul; 31(12):7759-7766. PMID: 39068317
Background: Despite trimodality treatment, 10% to 20% of patients with esophageal cancer experience interval metastases after surgery. Restaging may identify patients who should not proceed to surgery, as well as...
4.
Hermus M, van der Wilk B, Dekker J, Nieuwenhuijzen G, Rosman C, Timmermans L, et al.
Health Sci Rep . 2023 Dec; 6(12):e1725. PMID: 38111742
No abstract available.
5.
Valkema M, de Lussanet de la Sabloniere Q, Valkema R, Thomeer M, Dwarkasing R, Harteveld A, et al.
Nucl Med Commun . 2023 Nov; 45(2):128-138. PMID: 37982560
Purpose: The purpose of this study was to investigate whether 18F-fluorodeoxyglucose ( 18 F-FDG) PET/MRI may potentially improve tumor detection after neoadjuvant chemoradiotherapy (nCRT) for esophageal cancer. Methods: This was...
6.
van der Wilk B, Eyck B, Noordman B, Kranenburg L, Oppe M, Lagarde S, et al.
Ann Surg Oncol . 2023 Aug; 30(13):8192-8202. PMID: 37587357
Background: Esophagectomy is associated with lasting effect on health-related quality of life (HRQOL). Patients desire detailed information on the expected impact of treatment on their postoperative HRQOL. The aim of...
7.
Valkema M, Spaander M, Boonstra J, van Dieren J, Hazen W, Erkelens G, et al.
Br J Surg . 2023 Jul; 110(10):1381-1386. PMID: 37418342
Background: Active surveillance is being investigated as an alternative to standard surgery after neoadjuvant chemoradiotherapy for oesophageal cancer. It is unknown whether dysphagia persists or develops when the oesophagus is...
8.
Valkema M, Beukinga R, Chatterjee A, Woodruff H, van Klaveren D, Noordzij W, et al.
Nucl Med Commun . 2023 May; 44(8):709-718. PMID: 37132272
Objectives: Detection of residual oesophageal cancer after neoadjuvant chemoradiotherapy (nCRT) is important to guide treatment decisions regarding standard oesophagectomy or active surveillance. The aim was to validate previously developed 18...
9.
van der Zijden C, Lagarde S, Hermus M, Kranenburg L, van Lanschot J, Mostert B, et al.
BMC Cancer . 2023 Apr; 23(1):327. PMID: 37038138
Background: Neoadjuvant chemoradiotherapy (nCRT) followed by esophagectomy is a standard treatment for potentially curable esophageal cancer. Active surveillance in patients with a clinically complete response (cCR) 12 weeks after nCRT...
10.
Valkema M, Vos A, van der Post R, Ooms A, Oudijk L, Eyck B, et al.
J Pathol Clin Res . 2023 Mar; 9(4):322-335. PMID: 36971406
Oesophageal adenocarcinomas may show different histopathological patterns, including excessive acellular mucin pools, signet-ring cells (SRCs), and poorly cohesive cells (PCCs). These components have been suggested to correlate with poor outcomes...